Chargement en cours...
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Chinês |
| Publié: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
| Collection: | Chinese Journal of Lung Cancer |
| Sujets: | |
| Accès en ligne: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|